The Canadian Cancer Survivor Network has learned that BC Pharmacare has listed the newest bone-targeting agent on its formulary for men with advanced prostate cancer that has spread to their bones, who are considered palliative. While this is good news for these patients and a positive step forward, other men with prostate cancer that has spread to their bones, who are not palliative, are still being